Deucravacitinib shows promise in Pityriasis Rubra Pilaris study by Mayo Clinic
A study is underway to evaluate the safety and effectiveness of Deucravacitinib in patients with Pityriasis Rubra Pilaris.
Asset / Drug
Drug and asset intelligence for Deucravacitinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.